A strain of Vesicular Stomatitis virus, serotype Indiana (VSV), was compared after a single in vitro passage and after 16 in vitro passages in human white blood cells from patients suffering mostly from acute myeloid leukemia. The in vitro growth characteristics of these two virus lines in white blood cells (predominantly myeloblasts) from a patient with acute myeloid leukemia were measured, starting with low multiplicities of infection. No differences were seen in the following parameters: Length of latency phase, growth rate, final titer, thermal inactivation rate, plaque size, titer difference in chick embryo vs. human diploid cells, and extent of neutralization by a standard rabbit antiserum. Infectivity titrations in chick embryo cells gave consistently about ten times higher values than the same titrations done in human diploid cells, strain Wi38. More than 1,000 infectious units of VSV (as measured in chick embryo cells) were produced per myeloblast within 44 h. It was concluded that a single passage was sufficient to fully adapt VSV to human myeloblasts.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.